Adjuvant Effect of Cationic Liposomes for Subunit Influenza Vaccine: Influence of Antigen Loading Method, Cholesterol and Immune Modulators

A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant

(2013) Yvonne Perrie et al.   Human Vaccines & Immunotherapeutics

Cationic liposomes as adjuvants for influenza hemagglutinin: More than charge alone

(2012) Christophe Barnier Quer et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status

(2012) Karen Smith Korsholm et al.   Expert Review of Vaccines

Towards tailored vaccine delivery: Needs, challenges and perspectives

(2012) Jean-Pierre Amorij et al.   JOURNAL OF CONTROLLED RELEASE

A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog

(2012) Dennis Christensen et al.   JOURNAL OF CONTROLLED RELEASE

Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses

(2012) S.B. Rizwan et al.   JOURNAL OF CONTROLLED RELEASE

Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine

(2012) William C. Weldon et al.   PLoS One

Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

(2012) Douglas S. Watson et al.   VACCINE

Inactivated Influenza Vaccines

(2011) Valentina Parodi et al.   DRUGS & AGING

Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice

(2011) Suzanne M. Bal et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Adjuvant effect of cationic liposomes and CpG depends on administration route

(2011) Bram Slütter et al.   JOURNAL OF CONTROLLED RELEASE

Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination

(2011) C. Nembrini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling

(2011) Felix Geeraedts et al.   PLoS Pathogens

Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination

(2010) Suzanne M. Bal et al.   VACCINE

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy

(2009) Kaley D. Wilson et al.   ADVANCED DRUG DELIVERY REVIEWS

The Inflammasomes: Guardians of the Body

(2009) Fabio Martinon et al.   Annual Review of Immunology

Mechanism of action of clinically approved adjuvants

(2009) Bart N Lambrecht et al.   CURRENT OPINION IN IMMUNOLOGY

The path to a successful vaccine adjuvant – ‘The long and winding road’

(2009) Derek T. O’Hagan et al.   DRUG DISCOVERY TODAY

TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation

(2009) A. Larange et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens

(2008) Yvonne Perrie et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Antibodies and CD4+ T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain

(2008) Karoline Droebner et al.   VACCINE